WCG Wealth Advisors LLC Raises Position in Haleon PLC Sponsored ADR $HLN

WCG Wealth Advisors LLC increased its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 104.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 117,312 shares of the company’s stock after purchasing an additional 59,884 shares during the period. WCG Wealth Advisors LLC’s holdings in Haleon were worth $1,186,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in HLN. Norges Bank purchased a new position in shares of Haleon during the fourth quarter valued at approximately $163,529,000. Natixis Advisors LLC increased its holdings in Haleon by 429.8% during the fourth quarter. Natixis Advisors LLC now owns 10,003,941 shares of the company’s stock valued at $101,140,000 after buying an additional 8,115,633 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Haleon by 116.7% in the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock worth $128,423,000 after purchasing an additional 6,669,923 shares in the last quarter. Optiver Holding B.V. purchased a new stake in shares of Haleon in the third quarter worth $45,593,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Haleon by 36.6% in the third quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock worth $107,503,000 after purchasing an additional 3,207,986 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Argus raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, March 17th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Haleon has an average rating of “Moderate Buy”.

Haleon Stock Up 1.8%

NYSE:HLN opened at $9.13 on Friday. The company’s 50-day simple moving average is $9.43 and its 200-day simple moving average is $9.93. The stock has a market capitalization of $40.42 billion, a P/E ratio of 23.40, a P/E/G ratio of 2.04 and a beta of 0.13. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92. Haleon PLC Sponsored ADR has a fifty-two week low of $8.65 and a fifty-two week high of $11.28.

Haleon (NYSE:HLN) last released its earnings results on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The company had revenue of $3.65 billion during the quarter. On average, equities analysts anticipate that Haleon PLC Sponsored ADR will post 0.56 earnings per share for the current fiscal year.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.